FATP2-targeted therapies — A role beyond fatty liver disease. (November 2020)

• Record Type: Journal Article
• Authors: Qiu, Peishan; Wang, Haizhou; Zhang, Mengna; Zhang, Meng; Peng, Ruyi; Zhao, Qiu; Liu, Jing
• Is Part Of: Pharmacological research. Volume 161(2020)
• Publication Date: 2020-11
• Subjects: AA arachidonic acid -- AAV adeno-associated virus -- Acadm acyl-CoA dehydrogenase medium chain -- ACOX1 acyl-CoA oxidase -- ACSVL1 very long-chain acyl-CoA synthetase 1 -- ALT alanine aminotransferase -- AST aspartate aminotransferase -- BMI body mass index -- CKD chronic kidney disease -- CM conditioned media -- CoA coenzyme A -- CPT1α carnitine palmitoyltransferase 1α -- DEG differentially expressed gene -- DKD diabetic kidney disease -- ESRD end-stage renal disease -- FABP fatty acid-binding protein -- FAO fatty acid oxidation -- FATP fatty acid transport protein -- FATP2 fatty acid transport protein 2 -- Fat1p saccharomyces cerevisiae FATP orthologue -- FFA free fatty acid -- GDM gestational diabetes mellitus -- GFR glomerular filtration rate -- GM-CSF granulocyte-macrophage colony-stimulating factor -- Hadha hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit α -- HFD high-fat diet -- HIF-1α hypoxia-inducible factors 1α -- HIF-2α hypoxia-inducible factors 2α -- IDF International Diabetes Federation -- IL22RA1 interleukin 22 receptor subunit alpha 1 -- IRS insulin receptor substrate -- LCFA long-chain fatty acid -- NAFLD nonalcoholic fatty liver disease -- NEFA nonesterified fatty acid -- OCR oxygen consumption rate -- PA palmitic acid -- PGC-1α peroxisome proliferator-activated receptor γ coactivator-1α -- PGE2 prostaglandin E2 -- PMN-MDSCs polymorphonuclear myeloid-derived suppressor cells -- PPARα peroxisome proliferator-activated receptor α -- Ptges prostaglandin E synthase -- Ptgs2 prostaglandin-endoperoxide synthase 2 -- Retsat retinol saturase -- ROS reactive oxygen species -- shRNA short hairpin RNA -- Slc27a2 solute carrier family 27 member 2 -- STAT5 signal transducer and activator of transcription 5 -- T2DM type 2 diabetes mellitus -- TG triglycerides -- TGFβ transforming growth factor β -- TIFA TRAF interacting protein with forkhead associated domain -- UVR ultraviolet radiation -- VLCFA very long-chain fatty acid; Fatty acid transport protein -- Free fatty acids -- Lipid accumulation -- Cancer pathogenesis; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2020.105228
• Languages: English
• ISSNs: 1043-6618

Abstract

Graphical abstract: Abstract: Fatty acid transport protein 2 (FATP2) is a multifunctional protein whose specific function is determined by the type of located cell, its intracellular location, or organelle-specific interactions. In the different diseases setting, a newfound appreciation for the biological function of FATP2 has come into view. Two main functions of FATP2 are to activate long-chain fatty acids (LCFAs) as a very long-chain acyl-coenzyme A (CoA) synthetase (ACSVL) and to transport LCFAs as a fatty acid transporter. FATP2 is not only involved in the occurrence of nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM), but also plays an important role in lithogenic diet-induced cholelithiasis, the formation of cancer tumor immunity, the progression of chronic kidney disease (CKD), and the regulation of zoledronate-induced nephrotoxicity. Herein, we review the updated information on the role of FATP2 in related diseases. In particular, we discuss the new functions of FATP2 and propose that FATP2 is a potential clinical biomarker and therapeutic target. In conclusion, regulatory strategies for FATP2 may bring new treatment options for cancer and lipid metabolism-related disorders.